PacificGMP Completes GMP Product Fill for Trius Therapeutics

May 14, 2008, 01:00 ET from PacificGMP

    SAN DIEGO, May 14 /PRNewswire/ -- PacificGMP, the leader in utilizing
 single-use bioprocessing for development and manufacturing for its client
 partners, announced today that it has completed a product fill under GMP
 (good manufacturing practices) standards for a Trius Therapeutics Phase I
 clinical trial.
     "We are pleased to have worked closely with Trius on this GMP fill
 project, an effort that we were able to initiate quickly and complete
 within a narrow deadline," said Leigh N. Pierce, president of PacificGMP.
 "Although our client base consists of mainly biologics drug developers,
 PacificGMP has completed projects for a variety of other customers
 including small molecule drug developers like Trius, as well as academic
 institutions and diagnostics companies."
     "PacificGMP successfully completed our GMP product fill and I
 appreciated their flexibility and willingness to work with us to get the
 job done in a timely and professional manner," said Jeffrey Barker,
 Director of Pharmaceutical Development for Trius Therapeutics.
     About PacificGMP
     PacificGMP is a contract manufacturing organization (CMO) and industry
 leader in utilizing single-use bioprocessing for development and
 manufacturing of biologics. Single-use technology eliminates the risk of
 cross-contamination, has fewer system requirements and significantly
 reduces the time required to initiate production. Benefits to clients
 include rapid project turnaround and the most cost effective solution in
 the industry. PacificGMP provides cGMP and non-GMP services ranging from
 cell line optimization, early process design, development and scale-up, to
 preclinical and clinical biologics manufacturing, purification and
 fill/finish. More information can be found by visiting the Company's web
 site at
     About Trius Therapeutics
     Trius Therapeutics is discovering and developing innovative
 antibacterial drugs for the treatment of infections caused by resistant
 pathogens. The company's lead drug candidate, TR-701 is a novel, oral and
 IV, oxazolidinone antibiotic with potent activity against drug-resistant
 Gram-positive bacterial pathogens including those resistant to Zyvox(R).
 Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A
 Pharmaceuticals. Trius' pipeline includes two additional structure-based
 drug design programs directed against novel antibacterial targets. For more
 information, visit
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Leigh Pierce Contact: PacificGMP Gary Pierce Chief Business Officer 858-550-4094